Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma

74

SEATTLE–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/BLZ100?src=hash" target="_blank"gt;#BLZ100lt;/agt;–Blaze Bioscience announces the publication of Phase 1 clinical trial results for Tumor Paint: BLZ-100 (tozuleristide) in adults with glioma. http://www.businesswire.com/news/home/20190509005235/en/Blaze-Bioscience-Announces-Publication-Phase-1-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

- Advertisement -